The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
Dimopoulos
Meletios Athanasios
MA
Kastritis
Efstathios
E
Delimpassi
Sossana
S
Zomas
Athanasios
A
Kyrtsonis
Marie Christine
MC
Zervas
Konstantinos
K
D000368:Aged; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011379:Prognosis; D000069283:Rituximab; D012955:Societies, Medical; D015996:Survival Rate; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab